Clinical Trials Logo

POLD1 Gene Mutation clinical trials

View clinical trials related to POLD1 Gene Mutation.

Filter by:
  • None
  • Page 1

NCT ID: NCT05420064 Recruiting - BRCA1 Mutation Clinical Trials

An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate a cascade genetic testing intervention. Cascade testing is the process of offering genetic testing to people who are at risk of having inherited a possibly harmful gene change that has been found in their family. This process is repeated as more people within the family are found to have the gene change. The study will look at how often genetic testing occurs when healthcare providers have permission to reach out to family members to recommend genetic testing and to help those who are interested get tested. The study will look at whether this cascade testing intervention is practical and effective. The study would like to see how this approach of healthcare providers reaching out directly to family members compares with the usual approach of patients telling their family members about the recommendation to get genetic testing.

NCT ID: NCT05103969 Recruiting - Tumors Clinical Trials

Cohort of Tumors With POLE/D1 Mutation

Start date: October 5, 2021
Phase:
Study type: Observational

Primary objective of this study is to identify and describe the clinico-biological and molecular characteristics of tumors with somatic POLE (Polymerase ɛ)/POLD1 mutation identified by molecular biology platforms for all stages and primary sites combined

NCT ID: NCT03428802 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Start date: March 8, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating participants with cancer that has spread to other places in the body, has come back or has spread to nearby tissues or lymph nodes. Monoclonal antibodies such as, pembrolizumab, may interfere with the ability of tumor cells to grow and spread.